Overcoming HLA restriction in clinical trials Immune monitoring of mRNA-loaded DC therapy

OncoImmunology

Volumn 1, Issue 8, 2012, Pages 1392-1394

  Van Nuffel, An M T ^a   Wilgenhof, Sofie ^b   Thielemans, Kris ^a,b   Bonehill, Aude ^a  

^a FACULTY OF MEDICINE AND PHARMACY   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

DC therapy; Dendritic cells; HLA restriction; Immune monitoring; Skin infiltrating lymphocytes

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EPITOPE; IPILIMUMAB; MESSENGER RNA; VEMURAFENIB;

ADAPTIVE IMMUNITY; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL BASED GENE THERAPY; CLINICAL TRIAL (TOPIC); DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; HLA TYPING; HUMAN; IMMUNOGENICITY; IMMUNOMODULATION; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; MELANOMA; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL;

EID: 84886943603     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.20926     Document Type: Note

References (10)

1. Van Tendeloo VF, Van de Velde A, Van Driessche A, Cools N, Anguille S, Ladell K, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination. Proc Natl Acad Sci USA 2010; 107:13824-9; PMID:20631300; http://dx.doi.org/10.1073/pnas.1008051107.
2. Wilgenhof S, Van Nuffel AM, Corthals J, Heirman C, Tuyaerts S, Benteyn D, et al. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother 2011; 34:448-56; PMID:21577140; http://dx.doi.org/10.1097/CJI.0b013e31821dcb31.
3. Hänig J, Lutz MB. Suppression of mature dendritic cell function by regulatory T cells in vivo is abrogated by CD40 licensing. J Immunol 2008; 180:1405-13; PMID:18209035.
4. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003; 299:1033-6; PMID:12532024; http://dx.doi.org/10.1126/science.1078231.
5. Van Nuffel AM, Tuyaerts S, Benteyn D, Wilgenhof S, Corthals J, Heirman C, et al. Epitope and HLAtype independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens. J Immunol Methods 2012; 377:23-36; PMID:22269772; http://dx.doi.org/10.1016/j.jim.2011.12.010.
6. de Vries IJ, Bernsen MR, Lesterhuis WJ, Scharenborg NM, Strijk SP, Gerritsen MJ, et al. Immunomonitoring tumor-specific T cells in delayed-type hypersensitivity skin biopsies after dendritic cell vaccination correlates with clinical outcome. J Clin Oncol 2005; 23:5779-87; PMID:16110035; http://dx.doi.org/10.1200/JCO.2005.06.478.
7. Van Nuffel AM, Benteyn D, Wilgenhof S, Pierret L, Corthals J, Heirman C, et al. Dendritic Cells Loaded With mRNA Encoding Full-length Tumor Antigens Prime CD4(+) and CD8(+) T Cells in Melanoma Patients. Mol Ther 2012; 20:1063-74; PMID:22371843; http://dx.doi.org/10.1038/mt.2012.11.
8. Mullins DW, Sheasley SL, Ream RM, Bullock TN, Fu YX, Engelhard VH. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 2003; 198:1023-34; PMID:14530375; http://dx.doi.org/10.1084/jem.20021348.
9. Van Nuffel AM, Benteyn D, Wilgenhof S, Corthals J, Heirman C, Neyns B, et al. Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother 2011; PMID:22159452.
10. Van Lint S, Goyvaerts C, Maenhout S, Goethals L, Disy A, Benteyn D, et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 2012; 72:1661-71; PMID:22337996; http://dx.doi.org/10.1158/0008-5472.CAN-11-2957.